Drugs / Setipiprant
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02381496 | Dec 2011 → Apr 2012 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01877629 | Jul 2011 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02781311 | Jul 2016 → Mar 2018 | alopecia | Allergan | Completed | Missed primary |
| Phase 2 | NCT01225315 | Nov 2010 → Jan 2012 | asthma | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01241214 | Nov 2010 → Feb 2011 | seasonal allergic rhinitis | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01484119 Comparator | Dec 2011 → Feb 2012 | seasonal allergic rhinitis | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Setipiprant | “a CRTH2 antagonist (setipiprant)” PMID 28392807 ↗ Apr 2017 |
| Known as | ACT-129968 | “Multiple Doses of Setipiprant (ACT-129968)” NCT02381496 ↗ |
| Known as | KYTH-105 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2386081 ↗ |
| Action | Inhibit | “G protein-coupled receptor 44 antagonist” CHEMBL2386081 ↗1“(CRTH2) antagonist” NCT01877629 ↗ |
| Modality | Small molecule | “ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist” NCT01877629 ↗ |
| Route | Oral | “ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily” NCT01225315 ↗ |
| Target | PTGDR2 | “G protein-coupled receptor 44 antagonist” CHEMBL2386081 ↗ |